# Good T Cells

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/good-t-cells

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.goodtcells.co.kr
- Total disclosed funding: $35M
- Latest round: Series B (Dec 22, 2020)
- Investors on record: 10

## About

Based in Seoul, South Korea, and established in 2016, Good T Cells, Inc. is a biomedical company that developing immunotherapeutic and diagnostic reagents for cancer and autoimmune diseases. The company is developing immune cell therapy for solid tumors and autoimmune diseases. Candidate drugs, GTC110-04 treated for solid tumors, GTC12-01 treated for gastric cancer, and GTC10-01, GTC22-01, and GTC2330-01 treated for auto-immune diseased. The GTC10-01 and GTC110-04 have been entered into the pre-clinic trial phase, and other candidates' drugs have been in the discovery phase.

## Funding rounds

- Series B, Dec 22, 2020, $35M — AJU IB Investment, LB Investment, Seoul Investment Partners, Smilegate Investment, Posco Investment, ID Ventures, Albatross Investment, Union Investment Partners, Hana Ventures, DS Asset Management

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series B
- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series B
- Seoul Investment Partners (https://capitalatlas.ai/funds/seoul-investment-partners) — Series B
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series B
- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series B
- ID Ventures (https://capitalatlas.ai/funds/id-ventures) — Series B
- Albatross Investment (https://capitalatlas.ai/funds/albatross-investment) — Series B
- Union Investment Partners (https://capitalatlas.ai/funds/union-investment-partners) — Series B
- Hana Ventures — Series B
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series B